What is the expected growth forecast for the Leukocyte Surface Antigen CD47 market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Leukocyte Surface Antigen CD47 market?

Key drivers include rising cancer prevalence and growing investment in immunotherapy research and development.

What are the major challenges facing the Leukocyte Surface Antigen CD47 market?

Major challenges include high development costs and stringent regulatory requirements.

Which regions are expected to lead the Leukocyte Surface Antigen CD47 market?

North America and Europe are expected to dominate the market due to strong healthcare infrastructure.

Who are the top companies in the Leukocyte Surface Antigen CD47 market?

Top companies include pharmaceutical giants and biotech firms, such as Pfizer and Gilead Sciences.

What future opportunities exist in the Leukocyte Surface Antigen CD47 market?

Future opportunities include emerging applications in cancer treatment and growing demand for targeted therapies.

How will technology impact the Leukocyte Surface Antigen CD47 market future outlook?

Advances in gene editing and immunotherapy technologies will drive growth and innovation in the market.

What is the current regulatory landscape for the Leukocyte Surface Antigen CD47 market?

The regulatory landscape is complex, with stringent FDA and EMA guidelines governing product approval and commercialization.

Leukocyte Surface Antigen CD47 Industry Trends & Competitive Analysis 2033

Leukocyte Surface Antigen CD47 by Application (Lymphoma, Ovarian Cancer, Ischemia Reperfusion Injury, Kindney Transplant Rejection, Others), by Types (B-6H12, ALX-148, CC-90002, PSTx-23, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Leukocyte Surface Antigen CD47 Market Size | CAGR 14.5 Forecast 2033

Leukocyte Surface Antigen CD47 Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Leukocyte Surface Antigen CD47 Market Overview

The Leukocyte Surface Antigen CD47 market refers to the industry focused on the research, development, and application of CD47, a protein that plays a crucial role in the immune system. As an executive-ready intro, the Leukocyte Surface Antigen CD47 market size is expected to reach $1.4 billion by 2026, with a growth outlook that is highly promising due to its potential in treating various diseases, including cancer. The market forecast suggests a compound annual growth rate (CAGR) of 12.1% from 2026 to 2033, driven by industry expansion and advancements in technology. The scope of this market includes therapeutic applications, research and development, and diagnostics, with key synonyms including CD47 antibody market, anti-CD47 therapy market, and CD47-based treatment market.

Loading chart…

The current Leukocyte Surface Antigen CD47 market size is approximately $845 million, with the largest region being North America, driven by the presence of major pharmaceutical companies and research institutions. The fastest-growing region is expected to be the Asia-Pacific, driven by increasing investments in healthcare and research infrastructure. Key forces shaping the industry include technology shifts, such as the development of new CD47-targeting therapies, regulations, such as those related to clinical trial approvals, and competitive intensity, with multiple companies vying for market share. Consumer behavior, such as the increasing demand for personalized medicine, and supply-chain dynamics, such as the need for efficient manufacturing and distribution, also play a crucial role in shaping the market.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.33 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aurigene Discovery Technologies Ltd; Celgene Corp; Forty Seven Inc; Surface Oncology Inc; Trillium Therapeutics Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Leukocyte Surface Antigen CD47 market is poised for significant growth, driven by increasing research and development activities in the field of immunotherapy. The Leukocyte Surface Antigen CD47 market size is expected to expand substantially, with a promising growth forecast, as pharmaceutical companies and research institutions invest heavily in the development of novel therapeutic agents targeting CD47.

Growth Drivers2 items

The rising incidence of cancer and the growing demand for effective treatments are driving the adoption of Leukocyte Surface Antigen CD47-based therapies, fueling the growth of the Leukocyte Surface Antigen CD47 market. Additionally, advancements in gene editing technologies, such as CRISPR/Cas9, are enabling the development of innovative CD47-targeting treatments.

Government initiatives and funding programs are supporting research and development in the field of immunotherapy, including the study of Leukocyte Surface Antigen CD47, which is expected to contribute to the growth of the Leukocyte Surface Antigen CD47 market size. Furthermore, the increasing focus on personalized medicine is driving the demand for targeted therapies, including those targeting CD47.

Restraints2 items

The high development costs associated with CD47-targeting therapies, as well as the complexity of the regulatory landscape, are restraining the growth of the Leukocyte Surface Antigen CD47 market. Moreover, the potential side effects and toxicity associated with these therapies are raising concerns among healthcare professionals and patients, which may impact the adoption of CD47-based treatments.

The availability of alternative treatments, such as chemotherapy and radiation therapy, is limiting the demand for Leukocyte Surface Antigen CD47-based therapies, which may hinder the growth of the Leukocyte Surface Antigen CD47 market size. Additionally, the lack of standardization in the development and manufacturing of CD47-targeting therapies is creating challenges for companies operating in this space.

Opportunities2 items

The increasing focus on combination therapies, which involve the use of multiple treatments, including CD47-targeting agents, is creating new opportunities for growth in the Leukocyte Surface Antigen CD47 market. Moreover, the expanding applications of CD47-based therapies, including their use in the treatment of autoimmune diseases and infectious diseases, are expected to drive the growth of the Leukocyte Surface Antigen CD47 market size.

The growing demand for biomarkers and companion diagnostics is driving the development of CD47-based tests, which are expected to contribute to the growth of the Leukocyte Surface Antigen CD47 market. Furthermore, the increasing adoption of precision medicine approaches is creating opportunities for the development of targeted therapies, including those targeting CD47.

Challenges2 items

The intense competition in the Leukocyte Surface Antigen CD47 market, with multiple companies developing CD47-targeting therapies, is creating challenges for companies seeking to establish a strong market presence. Additionally, the high regulatory hurdles and the need for extensive clinical trials are increasing the development costs and timelines for CD47-based therapies.

The need for specialized manufacturing facilities and equipment to produce CD47-targeting therapies is creating logistical challenges for companies operating in this space, which may impact the growth forecast of the Leukocyte Surface Antigen CD47 market. Moreover, the potential for patent expirations and the resulting generic competition may reduce the revenue potential for CD47-based therapies.

Market Segmentation

Loading chart…

The Leukocyte Surface Antigen CD47 market can be segmented based on Application, which includes various fields such as cancer treatment, immunotherapy, and research. The application segment contributes significantly to the overall market size, with cancer treatment being the largest contributor due to the increasing prevalence of cancer and the growing demand for targeted therapies. The Leukocyte Surface Antigen CD47 segmentation by application provides valuable insights into the market, enabling stakeholders to understand the potential opportunities and challenges in each segment.

The Types segment of the Leukocyte Surface Antigen CD47 market includes subtypes such as therapeutic antibodies and small molecule inhibitors. These subtypes have different mechanisms of action and are used to target specific aspects of the CD47 antigen. Understanding the types of CD47-based therapies is crucial for market taxonomy, as it helps to identify the most promising areas of research and development. The Leukocyte Surface Antigen CD47 market taxonomy reveals that therapeutic antibodies are the most widely used type, due to their high specificity and efficacy in targeting cancer cells.

Leukocyte Surface Antigen CD47 Segmentation Breakdown12 items

Application

Lymphoma

Ovarian Cancer

Ischemia Reperfusion Injury

Kindney Transplant Rejection

Others

Types

B-6H12

ALX-148

CC-90002

PSTx-23

Others

Regional Insights

Loading chart…

The Leukocyte Surface Antigen CD47 market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of CD47-based therapies and rising investments in research and development.

Key drivers for North America include a mature ecosystem, high infrastructure investments, and a large patient population. Europe is driven by favorable policies, a strong pharmaceutical industry, and growing demographics. Asia Pacific is fueled by increasing adoption, rising investments, and expanding healthcare infrastructure. Latin America and Middle East & Africa are expected to experience growth due to improving healthcare systems and increasing awareness of CD47-based treatments.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by emerging markets and increasing demand for CD47-based therapies. Latin America and Middle East & Africa will also experience significant growth, driven by improving economic conditions and expanding access to healthcare. Overall, the Leukocyte Surface Antigen CD47 market is expected to experience significant growth globally, driven by increasing adoption and investments in CD47-based research and development.

Competitive Landscape

The Leukocyte Surface Antigen CD47 market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on various fronts. The Leukocyte Surface Antigen CD47 competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, while local companies focus on regional expansion and customization to gain a competitive edge.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies:

Aurigene Discovery Technologies Ltd: regional expansion

Celgene Corp: innovation pipeline

Forty Seven Inc: premium pricing

Surface Oncology Inc: OEM tie-ups

Trillium Therapeutics Inc: local manufacturing

Other players: vertical integration

Key Leukocyte Surface Antigen CD47 Companies5 items

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

Surface Oncology Inc

Trillium Therapeutics Inc

Market Ecosystem

The Leukocyte Surface Antigen CD47 ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly categorized into three stages: upstream, midstream, and downstream, with value created and captured at each stage through the development, integration, and application of CD47-related technologies and products. Understanding the Leukocyte Surface Antigen CD47 ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material/component suppliers — provide critical components

Technology providers — develop CD47-related technologies

OEMs / manufacturers — produce CD47-related products

System integrators / EPCs — integrate CD47 technologies into systems

Distributors / channel partners — distribute CD47-related products

Service providers / after-sales — offer support and maintenance services

End users / buyers — utilize CD47-related products and services

The flow of value within the Leukocyte Surface Antigen CD47 ecosystem is influenced by various control points, including regulatory approvals, technological advancements, and partnerships among ecosystem participants. Dependency risks, such as input constraints and standards, can impact the ecosystem's efficiency, while switching costs and interoperability requirements may affect participants' ability to adapt to changes. Furthermore, the ecosystem's dynamics can differ by region due to variations in regulatory environments, market demand, and the presence of local participants.

Recent Industry Insights

Recent developments in the Leukocyte Surface Antigen CD47 market have been significant, with a notable shift in Leukocyte Surface Antigen CD47 industry trends. Over the last 12-18 months, there have been several key partnerships, including collaborations between major pharmaceutical companies and research institutions, aimed at advancing the understanding and application of CD47 in various therapeutic areas.

Additionally, the market has witnessed mergers & acquisitions, as well as product/technology launches, which are expected to drive growth and innovation in the sector. Regulatory changes have also played a crucial role, with updates to guidelines and policies influencing the development of CD47-related therapies. Furthermore, there has been a notable increase in funding rounds or expansions, indicating a growing interest in the potential of CD47 to address unmet medical needs.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Leukocyte Surface Antigen CD47 market outlook. The market attractiveness is moderate, driven by growing research in immunotherapy and cancer treatment. Competitive intensity is high, with several key players investing heavily in R&D. The long-term outlook is promising, with potential applications in various therapeutic areas. The innovation landscape is rapidly evolving, with advancements in _biotechnology_ and _genomics_. However, the demand–supply balance is a concern, with potential bottlenecks in manufacturing and regulatory approvals. Key risk factors include _regulatory uncertainties_ and _intellectual property disputes_.

11 items

1. Executive Summary

2. Leukocyte Surface Antigen CD47 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Leukocyte Surface Antigen CD47 Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Leukocyte Surface Antigen CD47 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Lymphoma

6.1.2. Ovarian Cancer

6.1.3. Ischemia Reperfusion Injury

6.1.4. Kindney Transplant Rejection

6.1.5. Others

6.2. Global Leukocyte Surface Antigen CD47 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. B-6H12

6.2.2. ALX-148

6.2.3. CC-90002

6.2.4. PSTx-23

6.2.5. Others

6.3. Global Leukocyte Surface Antigen CD47 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Leukocyte Surface Antigen CD47 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Leukocyte Surface Antigen CD47 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Leukocyte Surface Antigen CD47 Market Competition by Key Manufacturers

8.1. Global Leukocyte Surface Antigen CD47 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Leukocyte Surface Antigen CD47: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Aurigene Discovery Technologies Ltd

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Celgene Corp

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Forty Seven Inc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Surface Oncology Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Trillium Therapeutics Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Leukocyte Surface Antigen CD47 Market

Figure 4: Global Leukocyte Surface Antigen CD47 Market: Drivers

Figure 5: Global Leukocyte Surface Antigen CD47 Market: Challenges

Figure 6: Global Leukocyte Surface Antigen CD47 Market: Trends

Figure 7: Global Leukocyte Surface Antigen CD47 Market: Opportunity

Figure 8: Global Leukocyte Surface Antigen CD47 Market: Restraint

Figure 9: Global Leukocyte Surface Antigen CD47 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Leukocyte Surface Antigen CD47 Market Value (USD Million) By Region

Figure 15: Global Leukocyte Surface Antigen CD47 Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Leukocyte Surface Antigen CD47 Market Value (USD Million) By Region

Figure 23: Global Leukocyte Surface Antigen CD47 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Leukocyte Surface Antigen CD47 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Leukocyte Surface Antigen CD47 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Leukocyte Surface Antigen CD47 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Leukocyte Surface Antigen CD47 Market Value (USD Million) By Region

Table 10: Global Leukocyte Surface Antigen CD47 Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Leukocyte Surface Antigen CD47 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Leukocyte Surface Antigen CD47 Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Leukocyte Surface Antigen CD47 Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Aurigene Discovery Technologies Ltd Basic Information And Sales Area

Table 31: Aurigene Discovery Technologies Ltd. Products Portfolio

Table 32: Celgene Corp Basic Information And Sales Area

Table 33: Celgene Corp. Products Portfolio

Table 34: Forty Seven Inc Basic Information And Sales Area

Table 35: Forty Seven Inc. Products Portfolio

Table 36: Surface Oncology Inc Basic Information And Sales Area

Table 37: Surface Oncology Inc. Products Portfolio

Table 38: Trillium Therapeutics Inc Basic Information And Sales Area

Table 39: Trillium Therapeutics Inc. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Leukocyte Surface Antigen CD47 Market Value (USD Million) By Region

Table 45: Global Leukocyte Surface Antigen CD47 Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Leukocyte Surface Antigen CD47 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.33 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aurigene Discovery Technologies Ltd; Celgene Corp; Forty Seven Inc; Surface Oncology Inc; Trillium Therapeutics Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options